Sign in
Active, not recruitingPhase 3

A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRX) Administered to Adults With Familial Chylomicronemia Syndrome (FCS) Previously Treated With Volanesorsen

Key facts

Who runs it
Ionis Pharmaceuticals, Inc.
Where
Ann Arbor, Boca Raton, Huntington Beach, and Rochester, United StatesSee the 4 sitesAlso in 2 other countries, 7 sites
Status
Active, not recruiting
Phase
Phase 3
People taking part
24 people enrolled
Started
25 Feb 2022
Expected to end
Jun 2027
Type of study
Interventional
Treatments tested
  • Olezarsen
Record updated
12 December 2025

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 4 criteriaShow less

Who can take part

  • Participants with FCS (clinical or genetic diagnosis) currently on or previously treated with volanesorsen (ISIS 304801); o Study participants in countries where Waylivra® is commercially approved and available for participants should not be deprived of the treatment option with Waylivra®. Participation in this study for such participants will only be allowed when Waylivra® was discontinued due to AEs
  • The following concomitant medications will be allowed if dosing regimen is expected to remain constant through the end of the study (occasional or intermittent use of over-the-counter (OTC) medications will be allowed at Investigator's discretion):; Statins, omega-3 fatty acids (prescription and OTC), fibrates, or other lipid-lowering medications. Participants taking OTC omega-3 fatty acids should make every effort to remain on the same brand through the end of the study; Antidiabetic medications; Oral anticoagulants (e.g., dabigatran, rivaroxaban, or apixaban, and warfarin with regular clinical monitoring); Tamoxifen, estrogens or progestins

Who cannot take part

  • Treatment with another investigational drug (non-oligonucleotide), biological agent, or device within 4 weeks of Screening, or 5 half-lives of investigational agent, whichever is longer
  • Concomitant medication/procedure restrictions:; Systemic corticosteroids or anabolic steroids within 6 weeks prior to Screening and during the study unless approved by the Sponsor Medical Monitor; Plasma apheresis within 4 weeks prior to Screening or planned during the study

Where in United States

Also in 2 other countries, 7 sites

  • University of Michigan, Department of Internal Medicine, Division of Metabolism, Endocrinology and Diabetes (MEND)Ann Arbor, United States
  • Excel Medical Clinical Trials, LLCBoca Raton, United States
  • Diabetes/Lipid Management & Research CenterHuntington Beach, United States
  • University of Rochester School of MedicineRochester, United States

About the trial

What the trial wants to find out

The purpose of the study is to evaluate the safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) effects of olezarsen (formerly known as AKCEA -APOCIII-LRX) in participants with FCS previously treated with volanesorsen.

The group in the trial

  • OlezarsenTreatment being tested

    Olezarsen will be administered once every 4 weeks by subcutaneous (SC) injection for up to 209 weeks.

Data and sources

Registry record
Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
An Open-Label Safety Study of AKCEA-APOCIII-LRX Administered Subcutaneously to Patients With Familial Chylomicronemia Syndrome (FCS) Previously Treated With Volanesorsen (ISIS 304801)
Record updated
12 December 2025